Kratom products require FDA warning labels

The New York Legislature approved file A05852 ("Kratom products require FDA warning labels"), by a recorded vote of 202 to 0. Last action: December 19, 2025.

New York file A05852, before the New York Legislature. Passed as of 2025-12-19.

What it does

Kratom packages must warn of FDA non-approval All kratom products sold in the state must now display a label stating the product has not been approved by the FDA and list known side effects, and cannot be labeled as 'all natural.'

The bigger picture

Market pressure on manufacturers to clarify product claims Kratom sellers must redesign packaging and marketing materials to comply, which may trigger broader industry shifts toward transparency or consolidation of smaller retailers unable to absorb compliance costs.

What to watch

Compliance costs and enforcement gaps may limit effect Small manufacturers and online retailers may face compliance expenses, and the bill's effectiveness depends on enforcement resources; consumers in bordering states or online marketplaces could still purchase non-compliant products.

How they voted

Yes (202)

Did not vote / other (11)

Read the official record for A05852

See everything up for a vote · This week in New York · See what we have filed with the clerk